Precision therapies take aim at non-Hodgkin’s lymphoma
Elie Dolgin • November 14, 2018
The dramatic success of ibrutinib has created a more hopeful reality for people with lymphoma, as targeted therapies fill the pipeline.
Continue reading here.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.
Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.